165 related articles for article (PubMed ID: 22274410)
1. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.
King MT; Viney R; Smith DP; Hossain I; Street D; Savage E; Fowler S; Berry MP; Stockler M; Cozzi P; Stricker P; Ward J; Armstrong BK
Br J Cancer; 2012 Feb; 106(4):638-45. PubMed ID: 22274410
[TBL] [Abstract][Full Text] [Related]
2. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
[TBL] [Abstract][Full Text] [Related]
3. Population-based study of long-term functional outcomes after prostate cancer treatment.
Carlsson S; Drevin L; Loeb S; Widmark A; Lissbrant IF; Robinson D; Johansson E; Stattin P; Fransson P
BJU Int; 2016 Jun; 117(6B):E36-45. PubMed ID: 25959859
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
5. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer.
Kyrdalen AE; Dahl AA; Hernes E; Småstuen MC; Fosså SD
BJU Int; 2013 Feb; 111(2):221-32. PubMed ID: 22672151
[TBL] [Abstract][Full Text] [Related]
6. Bother problems in prostate cancer patients after curative treatment.
Stensvold A; Dahl AA; Brennhovd B; Småstuen MC; Fosså SD; Lilleby W; Steinsvik A; Axcrona K; Smeland S
Urol Oncol; 2013 Oct; 31(7):1067-78. PubMed ID: 22341412
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.
Smith DP; King MT; Egger S; Berry MP; Stricker PD; Cozzi P; Ward J; O'Connell DL; Armstrong BK
BMJ; 2009 Nov; 339():b4817. PubMed ID: 19945997
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy.
Shrader-Bogen CL; Kjellberg JL; McPherson CP; Murray CL
Cancer; 1997 May; 79(10):1977-86. PubMed ID: 9149026
[TBL] [Abstract][Full Text] [Related]
11. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
Houédé N; Rébillard X; Bouvet S; Kabani S; Fabbro-Peray P; Trétarre B; Ménégaux F
BMC Cancer; 2020 Aug; 20(1):757. PubMed ID: 32787797
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced prostate cancer: effective treatments, but many adverse effects.
Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
14. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
[TBL] [Abstract][Full Text] [Related]
17. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
19. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.
Potosky AL; Legler J; Albertsen PC; Stanford JL; Gilliland FD; Hamilton AS; Eley JW; Stephenson RA; Harlan LC
J Natl Cancer Inst; 2000 Oct; 92(19):1582-92. PubMed ID: 11018094
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
